@article{8c23d949f0cf4e0faeb054fa94f6e864,
title = "Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.",
author = "J Naidoo and SJ Antonia and YL Wu and BC Cho and P Thiyagarajah and H Mann and MD Newton and C Faivre-Finn",
year = "2022",
month = jun,
day = "1",
language = "English",
volume = "40",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "Lippincott Williams \& Wilkins",
number = "16",
}